Rhode Island House Bill H7950

Rhode Island 2026 Regular Session

• Introduced: 2/27/26
• Refer: 2/27/26

Caption

Regulates price increases for prescription drugs.

Impact

If enacted, H7950 would significantly impact state laws governing pharmaceutical pricing and oversight. It establishes a mechanism for monitoring prescription drug prices and provides the state with the authority to impose hefty financial penalties on manufacturers who violate the specified pricing rules. This is expected to encourage fair pricing practices in the pharmaceutical market and, ultimately, enhance accessibility to medications for consumers in the state.

Summary

House Bill H7950 focuses on regulating price increases for prescription drugs in the state. Specifically, the bill imposes penalties on manufacturers for unsupported price increases of identified prescription drugs. An unsupported price increase is defined as a price rise that lacks adequate new clinical evidence justifying it. The penalty is set at 80% of the revenue difference between the sales of the drug at the increased price and the revenue that would have been generated had the wholesale acquisition cost been maintained from the previous year, with adjustments made for inflation.

Contention

There may be points of contention surrounding H7950 among stakeholders. Pharmaceutical companies may argue that the bill could lead to unintended consequences, such as manufacturers withdrawing drugs from the market to avoid penalties. Such actions could decrease competition and lead to drug shortages. On the other hand, consumer advocacy groups and some lawmakers are likely to support the bill as a necessary step to control soaring drug prices and demand accountability in the pharmaceutical industry.